Using blood tests and voice analysis to help diagnose dementia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study aims to evaluate the effectiveness of a blood test measuring neurofilament light chain levels and voice acoustic analysis in diagnosing dementia among individuals presenting with cognitive complaints. Participants will undergo a blood draw and speech assessment, with follow-up evaluations at 12 months to complete questionnaires and cognitive scales. The study also includes optional genetic testing for those at risk of fronto-temporal dementia, utilizing a simple saliva sample. The goal is to address the lack of standardized diagnostic tests for dementia and improve early detection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients presenting to Eastern Health services with a cognitive complaint or potential neurodegenerative disorder

Exclusion Criteria:

* Prognosis \<12 months
* No cognitive complaint
* Patients not involved within the single healthcare network

Where it's running

• Box Hill Hospital
  Box Hill, Victoria, Australia Recruiting
• Wantirna Health
  Wantirna, Victoria, Australia Recruiting

Study contacts

• Principal investigator: Prof. Amy Brodtmann, MBBS, FRACP, PhD, FANZAN — Monash University
• Study coordinator: Prof. Amy Brodtmann, MBBS, FRACP, PhD, FANZAN
• Email: amy.brodtmann@monash.edu
• Phone: 03 9094 9540

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes

  This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.

  Recruiting Center for Eye Research Australia · Melbourne, Victoria · NCT07545473

• Collecting data on neurodegenerative diseases progression markers

  This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.

  Recruiting IRCCS San Raffaele Roma · Cassino, Frosinone · NCT06596746

• Evaluating a new treatment for cognitive function in mild Alzheimer's dementia

  This study is testing a new treatment that combines brain stimulation and cognitive training to see if it can help people with mild Alzheimer's dementia improve their thinking skills.

  Recruiting at 11 sites Advanced Technology & Communications · Incheon, Bupyeong 6(yuk)-dong, Bupyeong-gu and 10 other locations · NCT06088121

• Effects of speech-language intervention on bilingual speakers with primary progressive aphasia

  This study tests if special speech therapy designed for bilingual people can help those with primary progressive aphasia communicate better in both of their languages.

  Recruiting at 2 sites University of Texas at Austin · Austin, Texas and 2 other locations · NCT05741853

• Cohort study on Alzheimer's risk in first-degree relatives

  This study looks at how likely first-degree relatives of Alzheimer's patients are to develop the disease themselves and what factors might affect that risk.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT05597410

• Using a passive home sensor to find digital signs of brain energy changes from nicotinamide riboside

  This project will try a contact-free home sensor to see if it can detect activity, sleep, and breathing changes related to nicotinamide riboside in people with mild cognitive impairment or mild Alzheimer's.

  Recruiting Mclean Hospital · Belmont, Massachusetts · NCT05245903

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.